Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
ID: 332384Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $499K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/332384

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic institutions and industrial organizations to translate scientific discoveries into practical tools for diagnosing and treating diseases, with a focus on innovative methods that address specific healthcare challenges. The program emphasizes the development of technologies in areas such as molecular diagnostics, imaging, and bioinformatics, ensuring applicability in various settings, including low-resource environments. Funding is available up to $499,000 annually for a maximum of five years, with applications due by January 8, 2025. For further details, applicants can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-166-Full-Announcement.html
    PAR-21-166.html
    The Department of Health and Human Services has issued a Funding Opportunity Announcement (FOA) aimed at establishing Academic-Industrial Partnerships to transform scientific discoveries into practical tools for disease diagnosis and treatment. This FOA, part of the NIH’s R01 Research Project Grant, encourages interdisciplinary collaboration between at least one academic institution and one industrial organization, focusing on innovative methods that target specific healthcare challenges. The initiative emphasizes technological advancements in molecular diagnostics, imaging, and bioinformatics, ensuring solutions are suitable for various settings, including low-resource environments. Funding is capped at $499,000 annually over a maximum of five years, with applications strictly excluding clinical trials. Key dates highlight ongoing submission cycles and reminders about changing guidelines for application formats. The program aims to bridge gaps in knowledge and execution, advancing research capabilities while facilitating the transition of promising technologies toward commercialization. Compliance with rigorous NIH application requirements is stressed, with detailed instructions for submission processes and eligibility criteria clearly outlined. This FOA reflects the federal government’s commitment to advancing healthcare technologies through collaborative research efforts.
    Similar Opportunities
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" (R01 - Clinical Trial Optional), aimed at fostering collaborations between academic and industrial organizations to develop innovative healthcare solutions. This initiative seeks to stimulate the translation of scientific discoveries into practical tools and methods for diagnosing and treating diseases, with a focus on interdisciplinary teamwork and addressing significant health challenges, particularly in low-resource settings. Eligible applicants can request funding up to $499,000 annually for a maximum project duration of five years, with the application deadline set for January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html.
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic institutions and industrial organizations to enhance imaging technologies for cancer diagnosis and treatment. This initiative seeks to translate scientific discoveries and engineering advancements into practical tools that address significant challenges in cancer research, focusing on the development and validation of imaging systems that improve detection and treatment monitoring. The grant offers a maximum budget of $500,000 per year for up to five years, with applications required to include at least one academic and one industrial investigator. Interested applicants can find more information and submit their proposals by the deadline of January 7, 2027, by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research between academic institutions and industrial partners to accelerate the development of innovative bioengineering tools addressing critical biomedical challenges. This initiative seeks multidisciplinary teams that integrate engineering principles to create robust solutions capable of enhancing life sciences understanding and medical practices within a 5-10 year timeframe. The program emphasizes the importance of partnerships in overcoming development barriers and facilitating technology validation and commercialization, ultimately aiming to improve patient health outcomes. Interested applicants can find more details and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting projects that develop innovative technologies to enhance biomedical research capabilities. Eligible applicants include a diverse range of institutions such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that have demonstrated proof of principle but still face significant technical challenges. This initiative emphasizes the development of laboratory instruments, algorithms, and biological systems, while applications targeting specific biomedical questions will not be funded. Interested parties should note that the application deadline is May 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-127.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)" aimed at developing medical technologies that address health disparities among underserved populations in the U.S. This initiative encourages grant applications focused on creating effective, affordable, culturally acceptable, and accessible medical solutions, including devices, imaging systems, and telehealth innovations, while emphasizing the importance of formal collaborations with healthcare organizations serving these populations. The NIH plans to allocate approximately $2.4 million for this initiative, with an award ceiling of $500,000 per project, and expects to fund 3-4 awards over a project duration of up to four years. Interested applicants must submit their proposals by May 2, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at advancing cancer treatment through innovative nanotechnology-based diagnostics and therapeutics. This initiative supports advanced pre-clinical research focused on developing nanoparticle and nano-device interventions that enhance the effectiveness of cancer treatments, particularly in combination therapy, immunotherapy, and imaging. The program emphasizes multidisciplinary collaboration and requires proposals to outline clear milestones for project advancement, with a maximum budget of $475,000 in direct costs annually over a project period of up to four years. Interested applicants must submit their proposals by November 17, 2024, and can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.